Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Thymic humoral factor gamma 2 is a synthetic or naturally derived octapeptide (sequence: Leu-Glu-Asp-Gly-Pro-Lys-Phe-Leu) essential for modulating immune responses[1]. It is purified from calf thymus extracts and demonstrates potent immunoregulatory effects, including enhancing lymphocyte (especially T cell) proliferation and cytokine production, particularly interleukin 2[1][2][3][4]. THF-gamma 2 has shown efficacy in restoring immunocompetence, such as T cell activity and cytokine production, in immunodeficient or aged animal models[2][6]. It also enhances immunotherapy efficacy in viral infections, such as cytomegalovirus[3][9], and demonstrates immunomodulatory potential in models of hepatic fibrosis and immune-mediated liver damage[8]. Investigational clinical uses have included management of immune deficiencies, viral infections (HIV, hepatitis B), and adjunct therapy in certain cancers[4][5][7]. THF-gamma 2 is considerably more potent than other thymic hormones like thymosin alpha 1 in augmenting immune function[2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thymic humoral factor gamma 2.